- Conditions
- Chronic Hepatitis C
- Interventions
- Daclatasvir, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 7
- States / cities
- Anaheim, California • Orlando, Florida • Baltimore, Maryland + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1729–1752
of 33,600
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acromegaly
- Interventions
- IONIS-GHR-LRx, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 3 more
- Conditions
- Uveal Melanoma
- Interventions
- IMCgp100
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Anti-human CCL24 monoclonal antibody (CM-101), Placebo
- Biological · Other
- Lead sponsor
- ChemomAb Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 8
- States / cities
- La Jolla, California • Sacramento, California • Chicago, Illinois + 4 more
- Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- AUTO3
- Biological
- Lead sponsor
- Autolus Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 7
- States / cities
- Duarte, California • Denver, Colorado • Miami, Florida + 4 more
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
- Drug
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 667 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 71
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more
- Conditions
- Solid Tumors
- Interventions
- KN035
- Drug
- Lead sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Lafayette, Indiana • San Antonio, Texas
- Conditions
- Metastatic NSCLC
- Interventions
- GME751, Keytruda-EU
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Fountain Valley, California
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
- Interventions
- Anhydrous Enol-oxaloacetate, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 74 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 9 Years · Male only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more
- Conditions
- Cystinuria
- Interventions
- Bucillamine
- Drug
- Lead sponsor
- Revive Therapeutics, Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Hiv
- Interventions
- Autologous CD4 T-Cells
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA, PTM CILO/FIR
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 175
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more
- Conditions
- Heart Disease
- Interventions
- EPA 600, EPA 1800, Olive Oil, DHA
- Dietary Supplement
- Lead sponsor
- Cardiovascular Research Associates
- Network
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Interventions
- Ocrelizumab (US), Ocrelizumab (EU), ABP 692
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Carlsbad, California + 24 more
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 1,773 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- Allogeneic Pancreatic Endocrine Cell Clusters
- Biological
- Lead sponsor
- Seraxis
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Urticaria
- Interventions
- GDC-0853
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 7 more
- Conditions
- HIV Infections
- Interventions
- Peginterferon alfa-2b
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months to 16 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 15
- States / cities
- Long Beach, California • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Necrotizing Enterocolitis
- Interventions
- STP206, Control
- Biological · Other
- Lead sponsor
- Leadiant Biosciences, Inc.
- Industry
- Eligibility
- 1 Day to 4 Days
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 13
- States / cities
- Hartford, Connecticut • Sunrise, Florida • Augusta, Georgia + 10 more
- Conditions
- HIV
- Interventions
- Atazanavir, Raltegravir, Ritonavir, Tenofovir/Emtricitabine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Verducatib, Placebo matching verducatib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Palma, California + 14 more
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- BGS649
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
- Conditions
- Plaque Psoriasis
- Interventions
- Etanercept, CHS-0214
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 521 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 43 more